Allergy Therapeutics PLC
LSE:AGY
Allergy Therapeutics PLC
LSE:AGY
Price:
2.875 GBX
Market Closed
Updated:
May 4, 2024
Allergy Therapeutics PLC
Operating Income
|
Allergy Therapeutics PLC
Operating Income Peer Comparison
Comparables:
GSK
AZN
INDV
HIK
DPH
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Operating Income
-£38.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£8.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
30%
|
CAGR 10-Years
9%
|
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$270m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$622m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is Allergy Therapeutics PLC's Operating Income?
Operating Income
-38.8m
GBP
-38.8m
GBP
Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Operating Income amounts to -38.8m GBP.
What is Allergy Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 5Y
-74%
-74%
Over the last year, the Operating Income growth was -43%.
You don't have any saved screeners yet
